CA3214399A1 - Treatment of cancer with kdm4 inhibitors - Google Patents

Treatment of cancer with kdm4 inhibitors Download PDF

Info

Publication number
CA3214399A1
CA3214399A1 CA3214399A CA3214399A CA3214399A1 CA 3214399 A1 CA3214399 A1 CA 3214399A1 CA 3214399 A CA3214399 A CA 3214399A CA 3214399 A CA3214399 A CA 3214399A CA 3214399 A1 CA3214399 A1 CA 3214399A1
Authority
CA
Canada
Prior art keywords
cancer
fold
diagnosed
cell
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214399A
Other languages
English (en)
French (fr)
Inventor
Frank Perabo
Jeffrey A. Stafford
Michael Clarke
Young K. Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tachyon Therapeutics Inc
Celgene Corp
Original Assignee
Tachyon Therapeutics Inc
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tachyon Therapeutics Inc, Celgene Corp filed Critical Tachyon Therapeutics Inc
Publication of CA3214399A1 publication Critical patent/CA3214399A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3214399A 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors Pending CA3214399A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163173219P 2021-04-09 2021-04-09
US63/173,219 2021-04-09
US202163252542P 2021-10-05 2021-10-05
US63/252,542 2021-10-05
US202263297960P 2022-01-10 2022-01-10
US63/297,960 2022-01-10
PCT/US2022/024087 WO2022217100A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Publications (1)

Publication Number Publication Date
CA3214399A1 true CA3214399A1 (en) 2022-10-13

Family

ID=83545127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214399A Pending CA3214399A1 (en) 2021-04-09 2022-04-08 Treatment of cancer with kdm4 inhibitors

Country Status (6)

Country Link
US (1) US20250025451A1 (enExample)
EP (1) EP4319748A4 (enExample)
JP (1) JP2024518712A (enExample)
AU (1) AU2022254741A1 (enExample)
CA (1) CA3214399A1 (enExample)
WO (1) WO2022217100A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2991090T3 (es) 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
JP2025532101A (ja) * 2022-09-21 2025-09-29 セルジーン コーポレーション ３－（｛［（４ｒ）－７－｛メチル［４－（プロパン－２－イル）フェニル］アミノ｝－３，４－ジヒドロ－２ｈ－１－ベンゾピラン－４－イル］メチル｝アミノ）ピリジン－４－カルボン酸のｌ－リジン塩、ヒストンデメチラーゼ阻害剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307643D0 (en) * 2003-04-02 2003-05-07 Cyclacel Ltd Markers
BR112015022391B1 (pt) * 2013-03-12 2021-12-21 Abbvie Inc Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos
US20160113911A1 (en) * 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
CN106660982B (zh) * 2014-06-25 2020-09-08 赛尔基因昆蒂赛尔研究公司 组蛋白脱甲基酶抑制剂
WO2018102736A1 (en) * 2016-12-01 2018-06-07 The General Hospital Corporation Methods for the treatment of cancer
ES2991090T3 (es) * 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
WO2018222831A1 (en) * 2017-05-31 2018-12-06 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA
WO2019083594A1 (en) * 2017-08-21 2019-05-02 The General Hospital Corporation COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES
UY38349A (es) * 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
AU2022331536A1 (en) * 2021-08-18 2024-02-22 Celgene Corporation Process for preparing histone demethylase inhibitors

Also Published As

Publication number Publication date
WO2022217100A1 (en) 2022-10-13
EP4319748A4 (en) 2025-02-26
EP4319748A1 (en) 2024-02-14
US20250025451A1 (en) 2025-01-23
JP2024518712A (ja) 2024-05-02
AU2022254741A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
JP7323592B2 (ja) 癌を治療するための併用療法
Braghini et al. Epigenetic remodelling in human hepatocellular carcinoma
Nachiyappan et al. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms
Liang et al. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer
US20220062240A1 (en) Methods of treating cancer using a clk inhibitor
EP3481963B1 (en) Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
He et al. Targeting cullin neddylation for cancer and fibrotic diseases
Ciuffreda et al. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations
Wang et al. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
US9597325B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
Prekovic et al. Molecular underpinnings of enzalutamide resistance
Chen et al. Hypomethylation-linked activation of PLCE1 impedes autophagy and promotes tumorigenesis through MDM2-mediated ubiquitination and destabilization of p53
WO2014138101A1 (en) Gene signature to predict homologous recombination (hr) deficient cancer
CN107614062A (zh) 用RORγ抑制剂治疗癌症的方法
JP7442439B2 (ja) Ｋｄｍ４阻害剤
US20250025451A1 (en) Treatment of cancer with kdm4 inhibitors
AU2020417223A1 (en) Treatment of cancer with CDK12/13 inhibitors
Tong et al. The emerging roles of histone demethylases in cancers
JP2025525935A (ja) 子宮漿液性がんを治療するためのｗｅｅ１化合物
CN110787296B (zh) 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒
EP4014047B1 (en) Ogdh inhibitors for use in the treatment of cancer
US11684601B2 (en) Treatment of cancer with combinations of agents
WO2009108755A2 (en) Pharmaceutical combinations for the treatment of cancer
WO2019039390A1 (ja) 若年性骨髄単球性白血病治療薬
AU2017279771A1 (en) Compositions and methods for treating cancer with aberrant lipogenic signaling

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260325

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260325

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260520